The US Food and Drug Administration (FDA) has approved a fixed-dose combination asthma treatment for patients aged twelve years and older.

Dulera combines an inhaled corticosteroid with a long-acting beta2-agonist (LABA) that opens airways and improves lung function.

The treatment is not indicated for the relief of acute bronchospasm – a condition common in asthmatics. It also carries a LABA black label warning.

Results of two Phase III studies to evaluate the safety and efficacy of Dulera showed that patients receiving the drug experienced significant improvement from baseline lung function.

The drug is developed by Merck and is expected to be available across the US by the end of July 2010.